gastrointestinal reactions
No significant difference was observed in the scores of the EORTC QLQ C30 questionnaire at baseline between the two groups (Table Quality of life before and after receiving interventions and chemotherapy treatment in different groups.Abbreviations: SD, standard deviation.After one cycle of chemotherapy and compound probiotic supplement/placebo treatment, the scores of the two groups (group BP‐1 vs. group C) showed a statistically significant difference in the following dimensions: overall quality of life (75.45 ± 15.46 vs. 61.55 ± 19.12, The prevalence of chemotherapy‐related gastrointestinal reactions between group BP‐1 and group C. (a) The incidence of chemotherapy‐related gastrointestinal reactions during the first cycle of chemotherapy. (b) The incidence of chemotherapy‐related gastrointestinal reactions during the second cycle of chemotherapy; *After 2 cycles of the study treatment, there was a significant difference in the dimensions, including overall quality of life (76.90 ± 18.31 vs. 58.89 ± 17.17, 